344 related articles for article (PubMed ID: 26719706)
1. The role of CD44 in epithelial-mesenchymal transition and cancer development.
Xu H; Tian Y; Yuan X; Wu H; Liu Q; Pestell RG; Wu K
Onco Targets Ther; 2015; 8():3783-92. PubMed ID: 26719706
[TBL] [Abstract][Full Text] [Related]
2. CD44 as a tumor biomarker and therapeutic target.
Xu H; Niu M; Yuan X; Wu K; Liu A
Exp Hematol Oncol; 2020 Dec; 9(1):36. PubMed ID: 33303029
[TBL] [Abstract][Full Text] [Related]
3. Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelial-mesenchymal transition in squamous cell carcinoma.
Geng S; Guo Y; Wang Q; Li L; Wang J
Arch Dermatol Res; 2013 Jan; 305(1):35-47. PubMed ID: 22740085
[TBL] [Abstract][Full Text] [Related]
4. Combination of epithelial-mesenchymal transition and cancer stem cell-like phenotypes has independent prognostic value in gastric cancer.
Ryu HS; Park DJ; Kim HH; Kim WH; Lee HS
Hum Pathol; 2012 Apr; 43(4):520-8. PubMed ID: 22018628
[TBL] [Abstract][Full Text] [Related]
5. Cancer stem cell and epithelial-mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast.
Oon ML; Thike AA; Tan SY; Tan PH
Breast Cancer Res Treat; 2015 Feb; 150(1):31-41. PubMed ID: 25677743
[TBL] [Abstract][Full Text] [Related]
6. The Prognostic Value of Cancer Stem Cell Markers (Notch1, ALDH1, and CD44) in Primary Colorectal Carcinoma.
Mohamed SY; Kaf RM; Ahmed MM; Elwan A; Ashour HR; Ibrahim A
J Gastrointest Cancer; 2019 Dec; 50(4):824-837. PubMed ID: 30136202
[TBL] [Abstract][Full Text] [Related]
7. The biology and role of CD44 in cancer progression: therapeutic implications.
Chen C; Zhao S; Karnad A; Freeman JW
J Hematol Oncol; 2018 May; 11(1):64. PubMed ID: 29747682
[TBL] [Abstract][Full Text] [Related]
8. The Prognostic Value of CD44 Expression in Epithelial-Mesenchymal Transition: Preliminary Data from Patients with Gastric and Esophageal Cancer.
Schizas D; Moris D; Kanavidis P; Michalinos A; Sioulas A; Pavlakis K; Machairas A; Liakakos T
In Vivo; 2016 11-12; 30(6):939-944. PubMed ID: 27815484
[TBL] [Abstract][Full Text] [Related]
9. Serglycin in tumor microenvironment promotes non-small cell lung cancer aggressiveness in a CD44-dependent manner.
Guo JY; Hsu HS; Tyan SW; Li FY; Shew JY; Lee WH; Chen JY
Oncogene; 2017 Apr; 36(17):2457-2471. PubMed ID: 27819672
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of CD44 variant 9 expression as a prognostic indicator in bladder cancer.
Kobayashi K; Matsumoto H; Matsuyama H; Fujii N; Inoue R; Yamamoto Y; Nagao K
Oncol Rep; 2016 Nov; 36(5):2852-2860. PubMed ID: 27599396
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of CD44 inhibits the invasion and metastasis of hepatocellular carcinoma both in vitro and in vivo by reversing epithelial-mesenchymal transition.
Gao Y; Ruan B; Liu W; Wang J; Yang X; Zhang Z; Li X; Duan J; Zhang F; Ding R; Tao K; Dou K
Oncotarget; 2015 Apr; 6(10):7828-37. PubMed ID: 25797261
[TBL] [Abstract][Full Text] [Related]
12. CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion.
Cho SH; Park YS; Kim HJ; Kim CH; Lim SW; Huh JW; Lee JH; Kim HR
Int J Oncol; 2012 Jul; 41(1):211-8. PubMed ID: 22552741
[TBL] [Abstract][Full Text] [Related]
13. Evidence for circulating cancer stem-like cells and epithelial-mesenchymal transition phenotype in the pleurospheres derived from lung adenocarcinoma using liquid biopsy.
Mirza S; Jain N; Rawal R
Tumour Biol; 2017 Mar; 39(3):1010428317695915. PubMed ID: 28347243
[TBL] [Abstract][Full Text] [Related]
14. CD44 Expression Predicts Prognosis of Ovarian Cancer Patients Through Promoting Epithelial-Mesenchymal Transition (EMT) by Regulating Snail, ZEB1, and Caveolin-1.
Zhou J; Du Y; Lu Y; Luan B; Xu C; Yu Y; Zhao H
Front Oncol; 2019; 9():802. PubMed ID: 31497537
[No Abstract] [Full Text] [Related]
15. CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer Prognosis.
Sosulski A; Horn H; Zhang L; Coletti C; Vathipadiekal V; Castro CM; Birrer MJ; Nagano O; Saya H; Lage K; Donahoe PK; Pépin D
PLoS One; 2016; 11(6):e0156595. PubMed ID: 27253518
[TBL] [Abstract][Full Text] [Related]
16. Predictive Value of CD44 in Muscle-Invasive Bladder Cancer and Its Relationship with IL-6 Signaling.
Wu CT; Lin WY; Chen WC; Chen MF
Ann Surg Oncol; 2018 Nov; 25(12):3518-3526. PubMed ID: 30128900
[TBL] [Abstract][Full Text] [Related]
17. CD44 as a cancer stem cell marker and its prognostic value in patients with ovarian carcinoma.
Bartakova A; Michalova K; Presl J; Vlasak P; Kostun J; Bouda J
J Obstet Gynaecol; 2018 Jan; 38(1):110-114. PubMed ID: 28816557
[TBL] [Abstract][Full Text] [Related]
18. CD44: A Multifunctional Cell Surface Adhesion Receptor Is a Regulator of Progression and Metastasis of Cancer Cells.
Senbanjo LT; Chellaiah MA
Front Cell Dev Biol; 2017; 5():18. PubMed ID: 28326306
[TBL] [Abstract][Full Text] [Related]
19. CD44 variant 6 is correlated with peritoneal dissemination and poor prognosis in patients with advanced epithelial ovarian cancer.
Tjhay F; Motohara T; Tayama S; Narantuya D; Fujimoto K; Guo J; Sakaguchi I; Honda R; Tashiro H; Katabuchi H
Cancer Sci; 2015 Oct; 106(10):1421-8. PubMed ID: 26250934
[TBL] [Abstract][Full Text] [Related]
20. Expression of TNF-α and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomas.
Mikami S; Mizuno R; Kosaka T; Saya H; Oya M; Okada Y
Int J Cancer; 2015 Apr; 136(7):1504-14. PubMed ID: 25123505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
